ICER hosted a multi-stakeholder policy summit to discuss methods for assessing the value of new drugs for rare conditions. The summit included discussion of how these methods can be applied to recommend fair prices that reflect the value of orphan drugs to patients and the health system to allow for broader insurance coverage for innovative […]
ICER produced a comprehensive white paper on diagnostic testing for Alzheimer’s disease that was presented to the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC). Date of review: January 2013 For questions, contact info@icer.org. Intervention of interest: Diagnostics for Alzheimer’s disease Final Documents Below you will find the final documents from the policy paper review […]
In January 2019, ICER launched a year-long project to engage with experts, US stakeholders, and influential international agencies to develop, test, and build consensus around methodological options for determining value-based prices for potential cures. ICER will ultimately create a roadmap for value assessment of potential cures that will have a direct and significant impact on […]
The combination of rising drug costs at the health system level and increasing financial stress for individual patients has triggered intense national concern. One target has come under particular scrutiny: rebates. Drug makers in the US face no federal process whereby prices are evaluated in comparison to evidence of clinical benefit, but they must negotiate […]